Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Controlled Study of Neoadjuvant LHRH-agonist Therapy and Permanent I-125 Implantation With vs. Without Adjuvant LHRH-agonist Therapy in Patients With Untreated Intermediate-risk Prostate Cancer.

NCT00664456 is registered in ClinicalTrials.gov with Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan as lead sponsor.

NCT NCT00664456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00664456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Controlled Study of Neoadjuvant LHRH-agonist Therapy and Permanent I-125 Implantation With vs. Without Adjuvant LHRH-agonist Therapy in Patients With Untreated Intermediate-risk Prostate Cancer.
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
June 30, 2023
Enrollment
421 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer